BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND CHD4, Mi2-BETA, 1108, ENSG00000111642, Mi-2b, DKFZp686E06161, Q14839 AND Treatment
7 results:

  • 1. MR features of primary bone lymphoma in children.
    Duffy P; Ecklund K
    Pediatr Radiol; 2023 Nov; 53(12):2400-2410. PubMed ID: 37770576
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.
    Gefard-Gontier E; Markich R; Zysman M; Veillon R; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Lefort F; Prey S; Dutriaux C; Gerard E; Dousset L; Pham-Ledard A; Beylot-Barry M; Schaeverbeke T; Kostine M
    Cancer Immunol Immunother; 2022 Nov; 71(11):2609-2618. PubMed ID: 35305123
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Racial Disparities in Children, Adolescents, and Young Adults with Hodgkin lymphoma Enrolled in the New York State Medicaid Program.
    Kahn JM; Zhang X; Kahn AR; Castellino SM; Neugut AI; Schymura MJ; Boscoe FP; Keegan THM
    J Adolesc Young Adult Oncol; 2022 Aug; 11(4):360-369. PubMed ID: 34637625
    [No Abstract]    [Full Text] [Related]  

  • 4. Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder.
    Van Keerberghen CA; Goffin K; Vergote V; Tousseyn T; Verhoef G; Laenen A; Vandenberghe P; Dierickx D; Gheysens O
    Acta Oncol; 2019 Jul; 58(7):1041-1047. PubMed ID: 31035840
    [No Abstract]    [Full Text] [Related]  

  • 5. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. High grade nonHodgkin's lymphoma: management with moderate dose combination chemotherapy.
    Palmer MC; Fitzharris BM; Robinson BA; Atkinson CH; Colls BM
    N Z Med J; 1988 May; 101(846):255-8. PubMed ID: 3374896
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Diffuse well-differentiated lymphocytic lymphoma: chemotherapy with BCNU, cyclophosphamide, vincristine, melphalan and prednisone.
    Case DC; Boyd M; Hayes DM; Dorsk BM
    Oncology; 1988; 45(6):417-20. PubMed ID: 3054672
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.